{"disease":{"id":"egfr-tki","name":"egfr tki"},"drugs":{"marketed":[{"drug_id":"osimertinib","indication_name":"Treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07124858","title":"Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Federation Francophone de Cancerologie Digestive","has_results":false},{"nct_id":"NCT05598528","title":"Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)","phase":"","overall_status":"RECRUITING","enrollment_count":210,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT06521034","title":"First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Yongchang Zhang","has_results":false},{"nct_id":"NCT04517526","title":"Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Shanghai Cancer Hospital, China","has_results":false},{"nct_id":"NCT03428022","title":"Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Shenzhen People's Hospital","has_results":false},{"nct_id":"NCT07498595","title":"TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Tianjin Medical University General Hospital","has_results":false},{"nct_id":"NCT05265793","title":"Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06643416","title":"Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Queen Mary Hospital, Hong Kong","has_results":false},{"nct_id":"NCT05663177","title":"Almonertinib Plus Metronomic Oral Vinorelbine","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT06766591","title":"Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Jiangsu Province Nanjing Brain Hospital","has_results":false},{"nct_id":"NCT06363734","title":"Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT02500927","title":"A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT04470076","title":"Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Fifth Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02575560","title":"Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Qingdao Central Hospital","has_results":false},{"nct_id":"NCT07298148","title":"Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":28,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06071013","title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT02206763","title":"Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":false},{"nct_id":"NCT05497076","title":"the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy","phase":"","overall_status":"UNKNOWN","enrollment_count":9,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}